&lt;p&gt;Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics&lt;/p&gt;

Wang, Lihong; Xie, Yalin; Fang, Hui; Xia, Zhengyuan; Pan, Hong; Yan, Senxiang

doi:10.2147/cmar.s200922

Cited by 4 publications

(4 citation statements)

References 34 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several lncRNAs have been documented to regulate the growth and metastasis of CC [11,12]. LncRNA differentiation antagonizing non-protein-coding RNA (DANCR) has recently been found to act as an oncogenic driver in several cancer type and correlated with tumor growth and metastasis [13]. Importantly, abnormal up-regulation of DANCR has been revealed to be linked with advanced tumor progression of CC [14].…”

Section: Introductionmentioning

confidence: 99%

Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells

Sun

Cao²,

Zhou

2020

BMC Cancer

View full text Add to dashboard Cite

Background The competing endogenous RNA (ceRNA) networks of long non-coding RNAs (lncRNAs) and microRNAs (miRs) have aroused wide concerns. The study aims to investigate the roles of lncRNA DANCR-associated ceRNA network in the growth and behaviors of colon cancer (CC) cells. Methods Differentially expressed lncRNAs between CC and paracancerous tissues were analyzed using microarrays and RT-qPCR. Follow-up studies were conducted to evaluate the correlation between DANCR expression and prognosis of CC patients. Loss-of-functions of DANCR were performed to identify its role in the malignant behaviors of CC cells. Sub-cellular localization of DANCR and the potential targets of DANCR were predicted and validated. Cells with inhibited DANCR were implanted into nude mice to evaluate the tumor formation and metastasis in vivo. Results DANCR was highly-expressed in CC tissues and cell lines, and higher levels of DANCR were linked with worse prognosis and less survival time of CC patients. Silencing of DANCR inhibited proliferation, viability, metastasis and resistance to death of CC cells. DANCR was found to be sub-localized in cytoplasmic matrix and to mediate murine double minute 2 (MDM2) expression through sponging miR-518a-3p in CC cells, during which the Smad2/3 signaling was activated. Likewise, silencing of DANCR in CC cells inhibited tumor formation and metastasis in vivo. Conclusion This study provided evidence that silencing of DANCR might inhibit the growth and metastasis of CC cells through the DANCR/miR-518a-3p/MDM2 ceRNA network and the defect of Smad2/3 while activation of the p53 signaling pathways. This study may offer novel insights in CC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells

Sun

Cao²,

Zhou

2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…The fixed-effect model was applied when I 2 > 50% and P > 0.05. Otherwise, the random-effect model was used [7]. The publication bias was assessed by the Funnel plots and Begg's test, and sensitivity analysis was performed to examine the robustness of results.…”

Section: Discussionmentioning

confidence: 99%

“…Numerous studies have suggested that lncRNAs play vital roles in various physiological and pathological process of cancers, including cell proliferation, migration, invasion, and metabolism by functioning as oncogene or tumor suppressor [4][5][6]. Furthermore, growing evidence has demonstrated that lncRNAs can be recognized as tumor-specific prognostic predictors for some cancers, and recent meta-analyses have suggested several lncRNAs correlated with prognosis and chinicopathological features as candidates for precise prognosis prediction of cancers, such as DANCR [7], CRNDE [8] and MVIH [9].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Dysregulation of the long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) has been found in multiple cancers. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. Methods: A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results: In total, 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56-2.52) with no heterogeneity (I 2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in those studies with digestive system cancers (HR = 2.05, 95% CI: 1.47-2.62), or with sample size < 70 (HR = 2.70, 95% CI: 1.29-4.11), or with multivariate analysis (HR = 2.04, 95% CI: 1.44-2.64). Moreover, elevated SNHG6 expression was positively associated with tumor invasion depth (OR = 1.76, 95% CI: 1.18-2.63), LNM (OR = 1.60, 95% CI: 1.18-2.17), DM (OR = 1.90, 95% CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95% CI: 1.36-2.60) in patients with cancers. Conclusions: High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

show abstract

“…An increasing number of studies have shown that lncRNA is abnormally expressed in many human cancers, and it plays an important role in the initiation and progression of cancer. Previous meta-analyses have indicated that ZEB1-AS1 [1], MALAT1 [2], SNHG1 [3], DANCR [4], and HOTAIR [5] are related to the clinicopathological features and prognosis of tumors. These findings demonstrate that lncRNA may be a tumor-specific prognostic biomarker and therapeutic target [6].…”

Section: Introductionmentioning

confidence: 99%

LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

et al. 2020

View full text Add to dashboard Cite

Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 （DLX6-AS1） is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (HR = 2.30, 95% CI: 1.70–3.09, P < 0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P < 0.01), tumor size (P < 0.01), lymph node metastasis (P < 0.01), and distant metastasis (P < 0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

show abstract

<p>Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics</p>

Cited by 4 publications

References 34 publications

Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells

Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells

Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis

LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

Contact Info

Product

Resources

About